{"task_id": "b0d162324286311c", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 179/464)", "text": "one plus etoposide)\nAcute Myelogenous Leukemia\n167\n\n--- Page 189 ---\nMANAGEMENT (CONT\u2019D)\n\u0002\nCONSOLIDATION TREATMENT\n\u0002\nCOMPLETE REMISSION POST-INDUCTION\n\u0002\nGOOD RISK\nchemotherapy IDAC or HDAC \u00033\n\u0002\nINTERMEDIATE RISK\nsibling donor allogeneic\nstem cell transplant (SCT) if available; other\nwise, consolidation chemotherapy\n\u0002\nPOORRISK\nallogeneicSCTifmatcheddonoravail\nable; otherwise, consolidation chemotherapy\n\u0002\nLACK OF COMPLETE REMISSION POST-INDUCTION\nrepeat induction or give cyclophosphamide\nplus etoposide. Proceed to consolidation as in\npoor risk disease if complete remission. Other\nwise, palliation only\n\u0002\nRELAPSE\nallogeneic SCT if matched donor avail\nable (preferred); otherwise, salvage chemotherapy\nwith\ncytarabine/carboplatin,\nclinical\ntrials,\nor\npalliation\nAGE >60\nindividualized treatment. If unable to tol\nerate aggressive therapy, consider IDAC with attenu\nated doses or palliation with hydroxyurea cytoreduction\nRelated Topics\nFebrile Neutropenia (p. 236)\nTumor Lysis Syndrome (p. 228)\nTREATMENT ISSUES\nCOMPLETE\nREMISSION\nnormal\nBM\ncellularity,\n<5% blasts in BM, none with leukemic phenotype or\nabnormal cytogenetics. Lumbar puncture after com\nplete remission with induction chemotherapy, espe\ncially those with monoblastic phenotype. After induc\ntion, the remission rate in younger patients (<55\nyears) is 70 85%, but only 40 50% in older patients\nALLOGENEIC SCT\nif HLA matched, may opt for\nconsolidation\nchemotherapy\nwhile\nwaiting\nfor\nmatch donor. Allogeneic SCT has resulted in cure\nrates of 50 60% for recipients in 1st remission\nSPECIFIC ENTITIES\nMYELODYSPLASTIC SYNDROME (MDS)\nopposite\nof myeloproliferative disorders, decreased cell counts\n\u0002\nSUBTYPES\nrefractory anemia (RA), refractory ane\nmia with ringed sideroblasts (RARS), refractory\nanemia with multilineage dysplasia, refractory\nanemia with multilineage dysplasia and ringed\nsideroblasts, refractory anemia with excess blasts\n(RAEB) 5 10% blasts, refractory anemia with\nexcess blasts in transformation (RAEB t) 10 19%\nblasts, MDS unclassified. RA and RARS are at low\nrisk of transforming to AML (i.e. >20% blasts),\nwhile the rest are at high risk\nSPECIFIC ENTITIES (CONT\u2019D)\n\u0002\nDIAGNOSIS\nperipheral blood smear (RBC with\nabnormal morphologic features, dysgranulopoi\nesis with Pelger Hue\u00a8t deformity, nuclear atypia\nand hypogranulation, relative monocytosis), bone\nmarrow biopsy\nINTERNATIONAL PROGNOSTIC SCORING\nSYSTEM FOR MYELODYSPLASTIC SYNDROMES\nScore\n0\n0.5\n1\n1.5\n2\n% blasts in\nBM\n<5\n5 10\n11 20\n21 30\nKaryotype\nGood\nMed.\nPoor\nCytopenia\n0/1\n2/3\nFor karyotype, good =\ny, del(5q), del(20q); med\nium = neither good nor poor; poor = chromosome\n7 or complex abnormalities\nRisk group\nScore\nMedian survival\nLow\n0\n5.7 years\nIntermediate 1\n0.5 1.0\n3.5 years\nIntermediate 2\n1.5 2.0\n1.2 years\nHigh\n\u00062.5\n0.4 year\n\u0002\nTREATMENTS\ntransfusions, EPO, treat infections\nearly, 5 azacytidine, lenalidomide, decitabine, allo\ngeneic stem cell transplant (IPSS \u00061.5)\nACUTE PROMYELOCYTIC LEUKEMIA(M3,APL,PML)\n\u0002\nPATHOPHYSIOLOGY\nassociated\nwith\nt(15;17)\n(q22;q21), which results in fusion of PML gene and\nretinoic acid receptor a gene. This gene product\nplays a key role in leukemogenesis. Other combina\ntions include t(11;17) with fusion of PLZF gene,\nt(5;17) with fusion of NPM gene, or t(11;17) with\nfusion of NuMA gene. Note that all except PLZF\nRARA are susceptible to retinoic acid treatment\n\u0002\nCLINICAL\nFEATURES\nsimilar to AML. DIC com\nmonly occurs in PML and should be monitored\nclosely\n\u0002\nTREATMENTS\ninduction\nwith\nall trans retinoic\nacid plus idarubicin, then consolidation with\nanthracycline and cytarabine, and then mainte\nnance with all trans retinoic acid for 1 year. Reti\nnoic acid exerts its effect via (1) degradation of\nPML RAR protein, (2) transformation of PML RAR\nfrom transcription repressor to activator, and (3)\ndifferentiation. Retinoic acid syndrome may occur\nwith fever, respiratory distress, interstitial pulmon\nary infiltrates, pleural and pericardial effusion, epi\nsodic hypotension, acute renal failure, and weight\ngain. Arsenic trioxide can be used for recurrent\ndisease but is associated with QT prolongation\nand sudden death\n168\nAcute Myelogenous Leukemia", "text_length": 4134, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 179/464)", "type": "chunk", "chunk_index": 178, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.491891", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.492630", "status": "complete", "chunks_added": 3}